Skip Navigation
Pipeline

Black Diamond’s Wholly Owned Pipeline

Target
Candidate / Indication
Preclinical
Phase 1
Phase 2
Phase 3
EGFR
  • Preclinical Completed Preclinical % Completed
  • Phase 1 Completed Phase 1 % Completed
  • Phase 2 50 % Completed
  • Phase 3 % Completed
Phase 2
  • Preclinical Completed Preclinical % Completed
  • Phase 1 50 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Phase 1
BRAF

BDTX-4933

KRAS-mutant NSCLC

BDTX-4933

RAF/RAS-mutant solid tumors
  • Preclinical Completed Preclinical % Completed
  • Phase 1 50 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Phase 1
FGFR2/3

BDTX-4876

Achondroplasia Multiple solid tumors
  • Preclinical 70 % Completed
  • Phase 1 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Preclinical
Undisclosed

Multiple solid tumors
  • Preclinical 70 % Completed
  • Phase 1 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Preclinical